Active substance
Bromocriptine
- SFDA 4
- US FDA 9
- Health Canada 2
- US price lines 3
- NHS prices 1
- WHO EML 1
- Safety 3
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| PARLODEL 2.5 MG TAB | 2.5 mg | Tablet · Oral use | 30 Bottle | SAR 54.10 | NCE · Prescription | Sandoz Pharmaceuticals | Valid |
| PARLODEL 2.5 MG TAB | 2.5 mg | Tablet · Oral use | 14 Blister | SAR 28.30 | NCE · Prescription | NOVARTIS | Withdrawn by MAH · Not Marketed |
| PARLODEL 2.5 MG TAB | 2.5 mg | Tablet · Oral use | 30 Blister | SAR 54.10 | NCE · Prescription | NOVARTIS | Withdrawn by MAH · Not Marketed |
| SEROCRYPTIN 2.5MG TAB | 2.5 mg | Tablet · Oral use | 30 Blister | SAR 30.90 | Generic · Prescription | SERONO | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ACROMEGALY; CARDIOMYOPATHY; HYPERPROLACTINEMIA; PARKINSONISM
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| PARLODEL | EQ 2.5MG BASE | tablet · oral | ESJAY PHARMA | Prescription | 28 Jun 1978 |
| PARLODEL | EQ 5MG BASE | capsule · oral | ESJAY PHARMA | Prescription | 28 Jun 1978 |
| BROMOCRIPTINE MESYLATE | EQ 2.5MG BASE | tablet · oral | SANDOZ | Prescription | 13 Jan 1998 |
| BROMOCRIPTINE MESYLATE | EQ 5MG BASE | capsule · oral | MYLAN | Prescription | 4 Apr 2005 |
| BROMOCRIPTINE MESYLATE | EQ 5MG BASE | capsule · oral | ZYDUS PHARMS USA INC | Prescription | 30 Jul 2008 |
| BROMOCRIPTINE MESYLATE | EQ 2.5MG BASE | tablet · oral | PADAGIS US | Prescription | 1 Oct 2008 |
| CYCLOSET | EQ 0.8MG BASE | tablet · oral | VEROSCIENCE | Prescription | 5 May 2009 |
| BROMOCRIPTINE MESYLATE | EQ 5MG BASE | capsule · oral | LEK PHARM | Discontinued | 10 Dec 1998 |
| BROMOCRIPTINE MESYLATE | EQ 2.5MG BASE | tablet · oral | AUROBINDO PHARMA USA | Discontinued | 24 Sep 2004 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| BROMOCRIPTINE | 02087324 | 2.5 MG | TABLET · ORAL | AA PHARMA INC |
| BROMOCRIPTINE | 02230454 | 5 MG | CAPSULE · ORAL | AA PHARMA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | BROMOCRIPTINE 2.5 MG TABLET | $1.60949 | per EA | 23 Sep 2026 |
| US NADAC | BROMOCRIPTINE 5 MG CAPSULE | $4.11666 | per EA | 17 Jun 2026 |
| US NADAC | CYCLOSET 0.8 MG TABLET | $5.25631 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Bromocriptine 2.5mg tablets | £17.55 | 30 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 18.8. Medicines for disorders of the pituitary hormone system · core
Therapeutic equivalent to cabergoline for Other specified benign neoplasm of endocrine glands
Safety signals and safety-related labeling changes
- US FDA 30 Jun 2026 PARLODEL — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - MHRA 24 Oct 2024 Bromocriptine: monitor blood pressure when prescribing bromocriptine for prevention or inhibition of post-partum physiological lactation
A safety review has been conducted by the MHRA following a Yellow Card report concerning a patient who was taking bromocriptine. The review concluded that blood pressure monitoring of patients prescribed with this drug is essential especially during the first days of treatment. - US FDA 17 Aug 2020 CYCLOSET — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.